Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options

An August $20 put on Stoke Therapeutics (STOK) is being discussed as a sell-to-open trade that yields a $2.25 premium, implying a $17.75 effective cost basis if exercised and a 20.2% annualized return if the option expires unexercised. At the time of the analysis STOK is trading at $30.01, so the strike requires a 33.7% decline to be put to the seller; the stock's trailing 12-month volatility is calculated at 70%, which the author suggests combining with fundamental analysis to judge reward versus risk.

Analysis

Market structure: The immediate winners are put sellers and options market-makers collecting the $2.25 premium (20.2% annualized) while downside is concentrated on equity holders if STOK falls >33.7% to trigger assignment. With trailing 12‑month volatility ~70%, options supply-demand is skewed toward yield-seeking sellers; large put issuance could increase downstream share supply if assigned and pressure equity price into stressed levels short-term.

Risk assessment: Tail risks are classic biotech binaries — clinical readout failure, negative FDA action, or a dilutive secondary within 3–12 months that can easily exceed 30% downside; IV spikes above 80% would signal market fear. On an immediate horizon (days) theta decay benefits sellers; over weeks/months trial/financial news and cash‑runway signals will dominate; long-term (quarters) outcome-dependent valuation re-rates are possible.

Trade implications: If comfortable owning STOK at $17.75, selling cash‑secured Aug $20 puts size 1–2% portfolio and cap assignment risk to that basis; alternative is a put credit spread (sell $20 / buy $15) to limit max loss. Hedge sector/systemic biotech exposure with a small long XBI put or buy STOK protective puts if holding shares; enter when IV≥65% and trim/close when premium compresses ~50% or IV falls >20 pts.

Contrarian angles: The consensus underestimates path‑dependency — collecting premium is not equity upside and IV=70% may already overprice routine volatility but underprice binary trial tail risk. Historical parallels: biotech IV often collapses post‑data; selling premium into IV spikes can work if you accept assignment risk, but crowded short‑put books risk forced share accumulation and subsequent dilution or margin moves. Monitor short interest and upcoming trial/FDA dates over next 30–180 days for asymmetric risk shifts.

Key Decisions for Investors

• Establish a size‑limited (1–2% portfolio) cash‑secured short position by selling Aug STOK $20 puts to collect ~$2.25; target effective buy‑in at $17.75 if assigned and exit if STOK trades above $25 within 30 days or premium halves.
• If unwilling to own shares, sell a put credit spread: short Aug $20 / long Aug $15 to cap downside; size at 0.5–1% portfolio to limit max loss to $4.75 per spread.
• If long STOK equity, buy 3‑6 month protective puts (e.g., $25 strike) costing no more than 3–4% of position to limit a >30% drawdown from current $30.01.
• Hedge sector exposure by buying a small hedge: long 1–2% notional of XBI 3‑6 month puts if implied volatility across biotech rises >20 pts vs SPX, to protect against correlated biotech selloff.
• Monitor four specific metrics before adding exposure: STOK short interest >15%, IV moves >80% (avoid initiating new short‑put), any FDA/trial readout date within 30–180 days, and cash runway/financing announcements — act to tighten stops or roll positions if any trigger occurs.